Sanofi - GSK SARS-CoV-2 Vaccine Description
Sanofi - GSK SARS-CoV-2 Vaccine candidate is a combination of innovative technologies to produce an adjuvanted SARS-CoV-2 vaccine to prevent COVID-19 disease.
The combination of a protein-based antigen together with an adjuvant is well-established and used in a number of vaccines available today. It can also improve the likelihood of delivering an effective vaccine that can be manufactured at scale.
Sanofi Pasteur will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology. This technology has produced an exact genetic match to proteins found on the surface of the SARS-CoV-2 virus, and the DNA sequence encoding this antigen has been combined into the DNA of the baculovirus expression platform, the basis of Sanofi’s licensed recombinant influenza product in the US.
GSK will contribute its proven pandemic adjuvant technology. An adjuvant is added to some vaccines to enhance the immune response and has been shown to create a stronger and longer-lasting immunity against infections than the vaccine alone.
Sanofi is one of the biggest firms seeking to produce a coronavirus preventive vaccine. It has partnered with U.K. based GlaxoSmithKline Plc (GSK) on the project supported by the U.S. and says it could make 600 million doses annually.
The companies have set up a Joint Task Force, co-chaired by David Loew, Global Head of Vaccines, Sanofi and Roger Connor, President Vaccines, GSK. This task force will seek to mobilize resources from both companies to look for every opportunity to accelerate the development of the candidate vaccine.
Sanofi - GSK SARS-CoV-2 Vaccine Indication
Sanofi - GSK SARS-CoV-2 Vaccine Candidate is indicated to prevent SARS-CoV-2 infection which leads to COVID-19 disease.
Sanofi - GSK SARS-CoV-2 Vaccine Dosage
Sanofi - GSK SARS-CoV-2 Vaccine Clinical Trials
The companies plan to initiate phase I clinical trials in the second half of 2020 and, if successful and subject to regulatory considerations, aim to complete the development required for the availability of the vaccine by the second half of 2021.
Sanofi - GSK SARS-CoV-2 Vaccine News
May 13, 2020 - Sanofi’s Chief Executive Officer Paul Hudson said in an interview with Bloomberg News, 'he warned that Europe risks falling behind unless it steps up efforts to seek protection against a pandemic that’s killed more than 290,000 people worldwide.
April 14, 2020 - Sanofi and GSK announce that they have signed a letter of intent to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic.
February 18, 2020 - David Loew, Sanofi’s global head of vaccines, announced the company would partner with the U.S. Biomedical Advanced Research and Development Authority—known as BARDA—to make a vaccine using the company’s recombinant DNA platform.